Elevated cholesterol levels, especially low lipoprotein cholesterol (LDL-C), leads to atherosclerosis—which may increase the risk of heart attack, stroke, and peripheral artery disease. Statins are common medications that can help lower cholesterol levels. However, myopathy can be a serious side effect that prevents patients from taking statins and significantly decreases overall quality of life. Described herein are dosage forms containing select combinations of natural herbal extracts and phytonutrients having the surprising ability to lower LDL-C levels in amounts comparable to statin drugs without noted side effects such as myopathy.

Elevated cholesterol levels, especially low lipoprotein cholesterol (LDL-C), leads to atherosclerosis—which may increase the risk of heart attack, stroke, and peripheral artery disease. Statins are common medications that can help lower cholesterol levels. However, myopathy can be a serious side effect that prevents patients from taking statins and significantly decreases overall quality of life. Described herein are dosage forms containing select combinations of natural herbal extracts and phytonutrients having the surprising ability to lower LDL-C levels in amounts comparable to statin drugs without noted side effects such as myopathy.

Provided is a kit comprising a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive; and a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof, and uses thereof in the treatment of pelvic pain arising from the female reproductive system. Further provided are methods of treatment of pelvic pain arising from a female reproductive system during a menstrual cycle, the method comprising administering during a first fraction of said menstrual cycle a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive, and administering during a second fraction of said menstrual cycle a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof.

Provided is a kit comprising a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive; and a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof, and uses thereof in the treatment of pelvic pain arising from the female reproductive system. Further provided are methods of treatment of pelvic pain arising from a female reproductive system during a menstrual cycle, the method comprising administering during a first fraction of said menstrual cycle a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive, and administering during a second fraction of said menstrual cycle a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof.

The present invention discloses Fuke Qianjin Capsules and a quality control method therefor. The capsules are made of Radix Et Caulis Flemingiae, Caulis Mahoniae, Herba Andrographis, Zanthoxylum dissitum Hemsl., Caulis Spatholobi, Radix Angelicae Sinensis, Radix Codonopsis, and Radix Rosa Laevigata as raw materials. Each of the Fuke Qianjin Capsules contains not less than 2.0 mg of Z-ligustilide, and a total amount of andrographolide and dehydroandrographolide is not less than 1.9 mg. A new standard for controlling quality of the Fuke Qianjin Capsules has been established through an analysis of chemical ingredients in the Fuke Qianjin Capsules. This standard adds a variety of core ingredient content to the existing pharmacopoeia standards. According to the Fuke Qianjin Capsules made in this range, the consistency of effects between different batches is more stable. Moreover, the more the types of core ingredients are limited, the more stable the consistency of the drug effect.

The present invention discloses Fuke Qianjin Capsules and a quality control method therefor. The capsules are made of Radix Et Caulis Flemingiae, Caulis Mahoniae, Herba Andrographis, Zanthoxylum dissitum Hemsl., Caulis Spatholobi, Radix Angelicae Sinensis, Radix Codonopsis, and Radix Rosa Laevigata as raw materials. Each of the Fuke Qianjin Capsules contains not less than 2.0 mg of Z-ligustilide, and a total amount of andrographolide and dehydroandrographolide is not less than 1.9 mg. A new standard for controlling quality of the Fuke Qianjin Capsules has been established through an analysis of chemical ingredients in the Fuke Qianjin Capsules. This standard adds a variety of core ingredient content to the existing pharmacopoeia standards. According to the Fuke Qianjin Capsules made in this range, the consistency of effects between different batches is more stable. Moreover, the more the types of core ingredients are limited, the more stable the consistency of the drug effect.

The present invention discloses Fuke Qianjin Capsules and a quality control method therefor. The capsules are made of Radix Et Caulis Flemingiae, Caulis Mahoniae, Herba Andrographis, Zanthoxylum dissitum Hemsl., Caulis Spatholobi, Radix Angelicae Sinensis, Radix Codonopsis, and Radix Rosa Laevigata as raw materials. Each of the Fuke Qianjin Capsules contains not less than 2.0 mg of Z-ligustilide, and a total amount of andrographolide and dehydroandrographolide is not less than 1.9 mg. A new standard for controlling quality of the Fuke Qianjin Capsules has been established through an analysis of chemical ingredients in the Fuke Qianjin Capsules. This standard adds a variety of core ingredient content to the existing pharmacopoeia standards. According to the Fuke Qianjin Capsules made in this range, the consistency of effects between different batches is more stable. Moreover, the more the types of core ingredients are limited, the more stable the consistency of the drug effect.

The present invention discloses a traditional Chinese medicine composition for treating diseases caused by human papillomavirus, a preparation method and use thereof. The traditional Chinese medicine composition comprises: 15-60 parts of Rhizoma Smilacis Glabrae, 7.5-30 parts of Sophora Flavescens, 10-40 parts of Herba Hedyotidis Diffusae, 10-40 parts of Herba Taraxaci, 6-24 parts of Dysosma Versipellis, 7.5-30 parts of Nidus Vespae, 10-40 parts of Cortex Phellodendri, 2.5-10 parts of Fructus Bruceae, 7.5-30 parts of Fructus Cnidii, 3-12 parts of Radix Glycyrrhizae, 7.5-30 parts of Flos Lonicerae, 7.5-30 parts of Folium Isatidis, 5-20 parts of Radix Semiaquilegiae, and 1000-2000 parts of 75% ethanol. The traditional Chinese medicine composition has good curative effect and good safety.

The present invention discloses a traditional Chinese medicine composition for treating diseases caused by human papillomavirus, a preparation method and use thereof. The traditional Chinese medicine composition comprises: 15-60 parts of Rhizoma Smilacis Glabrae, 7.5-30 parts of Sophora Flavescens, 10-40 parts of Herba Hedyotidis Diffusae, 10-40 parts of Herba Taraxaci, 6-24 parts of Dysosma Versipellis, 7.5-30 parts of Nidus Vespae, 10-40 parts of Cortex Phellodendri, 2.5-10 parts of Fructus Bruceae, 7.5-30 parts of Fructus Cnidii, 3-12 parts of Radix Glycyrrhizae, 7.5-30 parts of Flos Lonicerae, 7.5-30 parts of Folium Isatidis, 5-20 parts of Radix Semiaquilegiae, and 1000-2000 parts of 75% ethanol. The traditional Chinese medicine composition has good curative effect and good safety.

A method for inhibiting infection of SARS-CoV-2 in a subject is provided, including administering to the subject a compound, wherein the compound comprises Aromoline, Obamegine, Berbamine or Bersavine.